What if you'd held RARE?
A $1,000 investment in Ultragenyx Pharmaceutical Inc. (RARE) at the month-end close of 2014-01 would be worth $362 at the close of 2026-09 — -63.8% total return, dividends reinvested. The same $1,000 in the S&P 500, dividends reinvested, would be worth $5,404.
Your scenario
Result
If you'd bought $1,000 at the start of each year
Value of $1,000 invested on January 1 of each year, held to 2026-09, dividends included.
Every year, $1,000 from 2014
| Year | Value of $1,000 | Year return |
|---|---|---|
| 2014 | $1,000 | — |
| 2015 | $2,557 | +155.7% |
| 2016 | $1,602 | -37.3% |
| 2017 | $1,057 | -34.0% |
| 2018 | $991 | -6.3% |
| 2019 | $973 | -1.8% |
| 2020 | $3,155 | +224.1% |
| 2021 | $1,916 | -39.3% |
| 2022 | $1,056 | -44.9% |
| 2023 | $1,090 | +3.2% |
| 2024 | $959 | -12.0% |
| 2025 | $524 | -45.3% |
| 2026 | $349 | -33.5% |
Best and worst month-end to buy
The best single month-end close to have bought RARE was 2026-09 ($15.30): $1,000 then is $1,000 today. The worst was 2021-02 ($142): $1,000 then is $108.
FAQ
What would $1,000 in RARE be worth today?
A $1,000 investment in Ultragenyx Pharmaceutical Inc. (RARE) at the start of 2014 would be worth about $362 today, a total return of -63.8%. Dividends are reinvested in these figures.
What were the best and worst years for RARE?
Ultragenyx Pharmaceutical Inc. (RARE)'s strongest calendar year since 2014 was 2020, a +224.1% return — $1,000 held through that year became about $3,241 by year-end. Its weakest year was 2025, at -45.3%.
Does the calculator include dividends and splits?
Yes where available. Prices are adjusted for both stock splits and reinvested dividends (total return), the same measure brokerages use.
How much would $100 per month in RARE have grown?
Investing $100 at the end of every month since 2014-01 would have grown to about $4,676 on $15,300 invested.
Did RARE beat the S&P 500?
Over the same period, $1,000 in the S&P 500 with dividends reinvested (the S&P 500 Total Return index) would be worth $5,404. RARE trailed the S&P 500 by +93.3% in total return.
Is this investment advice?
No. Wall Street Regrets is an entertainment and education tool. Every number is a historical calculation, not a prediction, and past performance never guarantees future results.
Methodology
Ultragenyx Pharmaceutical Inc. (RARE) historical total-return data from 2014-01 to 2026-09, reduced to month-end closes for the tables above.
Returns use adjusted close prices — adjusted for stock splits and reinvested dividends, the same convention used by major brokerages. End-of-day and live prices come from EODHD; parts of the deep historical series are carried over from Yahoo Finance data. A "year" scenario invests $1,000 at the prior December's month-end close and values it at the latest available month-end close. Non-USD amounts are converted at historical month-end exchange rates (EODHD): to USD on the buy date and back to your currency at the latest rate, so the return reflects the currency move as well as the asset.
Month-end resolution means intra-month extremes are not captured in tables; the calculator uses exact trading-day closes where daily data is available. Figures ignore taxes, fees, and the currency effects of non-USD listings. History is not a forecast. Wall Street Regrets is entertainment, not investment advice.
What if you'd held…
Data: adjusted close prices via EODHD and Yahoo Finance. As of 2026-09-04. Not financial advice.